Here are the Impact of SLC22A1 rs12208357 on therapeutic response to metformin in type 2 diabetes patients journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
Impact office supplies, impact of ai on jobs, impact of us tariffs on india, impact of us tariffs 2025, impact of shutdown on jobs, impact of oregon, impact of event scale revised, impact of climate change, impact of ai on the environment.
Impact of SLC22A1 rs12208357 on therapeutic response to metformin in type 2 diabetes patients
Introduction: : Metformin, an oral hypoglycemic agent, is generally used as the first-line treatment in type 2 diabetes mellitus (T2DM) patients. The response to metformin varies between patients, and its mechanisms remain incompletely understood. Genetic variations in proteins involved in the pharmacodynamics and pharmacokinetics of metformin, like OCT1 transporter, are suspected to explain this difference. This study investigated the association of the response to metformin in T2DM patients with the presence of rs12208357 (R61C) variant in the SLC22A1 gene. Materials and
methods: We selected 100 patients who responded and 100 patients who did not respond to metformin monotherapy after 20 weeks according to their HbA1c level change. We investigated the effect of rs12208357 on the structure, function, and stability of OCT1 protein and its interaction with metformin by in silico tools. To determine the genotype of rs12208357 we used the ARMS-PCR techniq ue.
Results: The in silico study indicated that rs12208357 probably changes OCT1 stability, function, interaction site, and binding energy to metformin in the extracellular domain. ARMS-PCR also showed the frequency of T and C alleles were significantly different between responders and non-responders (P-value = 0.014), also there is a significant difference in CC and CT/TT genotype frequency between responders and non-responders (P-value = 0.023).
Conclusion: Based on the in silico study and ARMS-PCR experiment results, the CC genotype has a better response to metformin therapy and the carrier of the T allele (CT and TT genotype) probably has complications in glycemic control by metformin. © The Author(s), under exclusive licence to Tehran University of Medical Sciences 2024.
Authors : Moazzami R.; Mehrjardi M.Y.V.; Miri A.
Source : Springer Science and Business Media Deutschland GmbH
Article Information
| Year | 2024 |
| Type | Article |
| DOI | 10.1007/s40200-024-01486-4 |
| ISSN | 22516581 |
| Volume | 23 |
You can download the article here
If You have any problem, contact us here